Explorez tous les épisodes du podcast CME in Minutes: Education in Cardiology & Pulmonology

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/KNY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Barbara Melosky, MD, FRCPC; and Alyson Chin, RN, BScN, MN-ACNP(A). In this activity, experts in lung cancer discuss the management of adverse events associated with tyrosine kinase inhibitor use in patients with ALK-positive metastatic non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Identify ALK tyrosine kinase inhibitor (TKI)–related adverse events (AEs) among patients with ALK-positive (ALK+) metastatic non–small-cell lung cancer (mNSCLC); Apply strategies to effectively monitor and manage ALK TKI–related AEs to enhance treatment adherence in patients with ALK+ mNSCLC; and Outline multidisciplinary, patient-centered strategies to optimize care for patients receiving ALK TKIs for ALK+ mNSCLC.

Please visit answersincme.com/860/103760795-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; Mike Sharma, MD, MSc; and Eddie Needham, MD, FAAFP. In this activity, experts in atrial fibrillation (AF) discuss evidence-based strategies to optimize stroke prevention, address anticoagulation gaps in clinical practice, and prepare for emerging approaches to anticoagulation. Upon completion of this activity, participants should be better able to: Apply evidence-based risk stratification tools and guidelines to address anticoagulation gaps in primary care patients with AF; Assess the clinical impact of suboptimal anticoagulation on AF stroke prevention; Evaluate emerging strategies for AF stroke prevention, including factor XI/XIa inhibitors; and Outline multidisciplinary, equity-focused care strategies incorporating social determinants to optimize AF stroke prevention in diverse populations.

Please visit answersincme.com/860/103117485-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and David Harpole, MD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss current and emerging strategies for sequencing therapies beyond progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/103117485-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Benjamin Levy, MD, FASCO. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss how tumor biology and genomic reassessment can guide sequencing after first-line progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/103117485-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Pasi A. Jänne, MD, PhD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss practical strategies for optimizing first-line testing and treatment selection. Upon completion of this series, participants should be better able to: Interpret updated evidence and recommendations regarding first-line testing and treatment selection for patients with advanced EGFR-mutated NSCLC; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH requiring treatment escalation.

Please visit answersincme.com/860/IME_2025_00013162-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Toby Maher, MB, MSc, PhD, FRCP; and Justin Oldham, MD, MS. In this activity, experts explore advances in ILD care, including personalized, multidisciplinary approaches to integrate novel antifibrotic therapy and enhance patient engagement. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel antifibrotic therapy in interstitial lung disease (ILD); Apply the latest clinical data on novel antifibrotic therapy to therapeutic decision-making in ILD; and Outline multidisciplinary strategies to enhance the care of patients with ILD who are receiving antifibrotic therapies.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of current and emerging HER2-targeted treatments; and Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NSCLC; and Assess which patients may be candidates for approved oral HER2-targeting TKIs in the context of the current standard of care.

Please visit answersincme.com/GYB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Pasi A. Jänne, MD, PhD, FASCO. In this activity, an expert in oncology discusses the role of emerging KRAS inhibitors in the treatment paradigm for non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for targeted therapy in previously untreated patients with KRAS-mutant NSCLC in the context of current standard of care with chemoimmunotherapy; Interpret the clinical evidence for emerging KRAS inhibitors in patients with previously untreated NSCLC; and Propose how emerging KRAS inhibitors may fit into the treatment paradigm for treatment-naive patients with KRAS-mutant NSCLC.

Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.

Please visit answersincme.com/860/102701687-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Mike Sharma, MD, MSc; and Richard A. Bernstein, MD, PhD. In this activity, experts in stroke discuss post-stroke care and long-term secondary stroke prevention. Upon completion of this activity, participants should be better able to: Discuss evidence-based strategies for secondary stroke prevention, including risk factor modification; Outline the potential role of FXIa inhibitors in closing current long-term management gaps for patients who have had a non-cardioembolic ischemic stroke or TIA; and Design multidisciplinary, long-term secondary stroke treatment plans that effectively leverage all members of the stroke care team, including cardiologists.

Please visit answersincme.com/860/101064703-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Muthiah Vaduganathan, MD, MPH and Nosheen Reza, MD, MS. In this activity, experts in cardio-kidney-metabolic syndrome (CKM) discuss emerging evidence on nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and practical strategies for incorporating these therapies into care for patients with heart failure, with or without chronic kidney disease (CKD) or type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Specify the rationale for nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) as treatment for adult patients with HF, with or without CKD or T2D; Differentiate the risk-benefit profiles between nsMRAs and the current standard of care for the treatment of HFmrEF or HFpEF, based on the available evidence; and Recommend patient-centered, long-term care strategies to integrate nsMRAs into clinical practice for patients with HF, with or without overlapping CKD or T2D.

Please visit answersincme.com/BGQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Marianna Fontana, MD, PhD. In this activity, an expert in cardiology discusses the role of biomarkers and disease-modifying therapies in transthyretin amyloid cardiomyopathy (ATTR-CM). Upon completion of this activity, participants should be better able to: "Differentiate the mechanisms of action and pharmacologic profiles of approved transthyretin (TTR) stabilizers and TTR silencers; Recognize the role of biomarkers and clinical disease features in transthyretin amyloid cardiomyopathy (ATTR-CM) disease assessment and treatment monitoring; and Interpret the latest available data for approved treatments for ATTR-CM.

Please visit answersincme.com/860/102620367-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; and Henry J. Michtalik, MD, MPH, MHS. IIn this activity, experts in preventive cardiology and hospital medicine discuss secondary stroke prevention strategies for hospitalists and internists. Upon completion of this activity, participants should be better able to: Evaluate guideline-recommended secondary stroke prevention strategies after ischemic stroke or TIA; Describe the clinical rationale for FXIa inhibitors; Discuss the clinical significance of the latest efficacy and safety data for FXIa inhibitors in secondary stroke prevention; and Apply best practices for transitioning patients from inpatient to outpatient secondary stroke prevention care.

Please visit answersincme.com/FGV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Janet B. McGill, MD, MA, FACP, MACE. In this activity, an expert in the management of diabetes discusses evolving data on emerging strategies to enhance cardiorenal outcomes in patients with type 1 diabetes (T1D). Upon completion of this activity, participants should be better able to: Review the limitations of current treatment strategies for chronic kidney disease (CKD) in type 1 diabetes (T1D); Identify the pathophysiologic mechanisms underlying CKD in patients with T1D; and Assess current and emerging treatment strategies for their potential to improve cardiorenal outcomes in patients with T1D.

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the implications of real-world data on biologic therapies for addressing airway remodeling and airway plugging; Develop steroid-sparing treatment plans and monitoring strategies for patients with severe eosinophilic asthma; and Formulate treatment plans to adjust the use of biologic therapies in patients with severe eosinophilic asthma and overlapping eosinophilic comorbidities.

Please visit answersincme.com/860/MED-CMB-03166-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Samuel S. Gidding, MD; Pamela B. Morris, MD, FACC and Allison Jamison. In this activity, experts in homozygous familial hypercholesterolemia (HoFH) discuss screening, diagnosis, and treatment strategies to support effective management of this rare inherited lipid disorder. Upon completion of this activity, participants should be better able to: Identify strategies to screen and diagnose HoFH; Review the treatment landscape of HoFH, including the role of LDLR-independent therapies; and Outline patient-centered practical strategies to enhance the management of children and adults with HoFH.

Please visit answersincme.com/860/120773-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alex Spira, MD, PhD, FASCO; and Kathryn C. Arbour, MD. In this activity "In this activity, experts in oncology discuss the evolving role of RAS(ON) inhibitors in shaping future treatment strategies for patients with KRAS-mutated non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Identify areas of unmet need in KRAS-mutant NSCLC across diverse KRAS variants in pretreated advanced settings; Describe the rationale for the use of RAS(ON) inhibitors for patients with KRAS-mutated NSCLC, based on evidence; and Assess how RAS(ON) inhibitors may be optimally used in clinical practice as they become available.

Please visit answersincme.com/RCG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Raymond Osarogiagbon, MD, MBBS, FACP, FASCO; and Michael Gieske, MD. In this activity, experts in lung cancer discuss practical strategies for lung cancer screening. Upon completion of this activity, participants should be better able to: Recognize barriers to achieving lung cancer screening for eligible patients; Identify patients at high risk of lung cancer who are eligible for screening; and Outline practical, patient-centered strategies to appropriately integrate lung cancer screening into routine practice.

Please visit answersincme.com/JRV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lung cancer discusses the use of immunotherapy in clinical practice for patients with limited-stage (LS) and extended-stage (ES) small-cell lung cancer (SCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of immune checkpoint inhibitors in LS-SCLC and ES-SCLC; Assess the clinical profiles of approved and emerging immune checkpoint inhibitor therapies for LS-SCLC and ES-SCLC; and Outline evidence-based strategies for incorporating immune checkpoint inhibitor therapy into treatment plans for patients with LS-SCLC and ES-SCLC.

Please visit answersincme.com/860/99097105-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in small cell lung cancer (SCLC) discuss the pathophysiologic rationale, emerging clinical evidence, and potential future role for B7-H3–directed antibody-drug conjugates in extensive-stage SCLC. Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating B7-H3–directed antibody-drug conjugates (ADCs) in the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC); Analyze recent clinical trial findings on B7-H3–directed ADCs in patients with previously treated ES-SCLC; and Formulate evidence-based, multidisciplinary team strategies for incorporating B7-H3–directed ADCs into treatment plans for patients with ES-SCLC, as they become available.

Please visit answersincme.com/860/MED-RESP-03658-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in pulmonary medicine discuss how to integrate biologics into individualized treatment plans for chronic obstructive pulmonary disease (COPD), featuring insights from a patient advocate. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting eosinophilic inflammation in COPD; Differentiate available and late-stage emerging biologic therapies based on the latest clinical evidence in COPD; Identify patients with COPD who are appropriate candidates for biologic therapy; and Outline strategies to optimally incorporate biologic therapies into treatment plans for patients with COPD.

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.

Please visit answersincme.com/860/97851223-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the latest advances in the treatment of small-cell lung cancer (SCLC), including both extensive-stage and limited-stage disease. Upon completion of this activity, participants should be better able to: Identify clinical factors that drive treatment decision-making for patients with SCLC; and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

Please visit answersincme.com/860/97851223-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the growing importance of immunotherapy in the management of limited-stage small-cell lung cancer (LS-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Identify clinical factors that drive treatment decision-making for patients with SCLC.

Please visit answersincme.com/860/MED-RESP-03268-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, a family medicine physician and a pulmonologist discuss strategies for optimizing chronic obstructive pulmonary disease (COPD) detection and management in primary care. Upon completion of this activity, participants should be better able to: Review the latest guideline recommendations on the management of COPD; Identify the impact of approved follow-up pharmacotherapies in the treatment of COPD; and Determine personalized strategies to incorporate follow-up pharmacotherapies into clinical practice for COPD.

Please visit answersincme.com/XVH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the role of biologic therapy in patients with eosinophilic chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify patients with unmet therapeutic needs despite guideline-recommended management of chronic obstructive pulmonary disease (COPD); Review the clinical rationale for approved and emerging biologics targeting type 2 inflammation in the treatment of eosinophilic COPD; and Assess strategies to incorporate biologics targeting type 2 inflammation into clinical practice for COPD, as they become available.

Please visit answersincme.com/860/98320325-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the evolving role of HER2-targeted antibody–drug conjugates (ADCs) and how to integrate them into clinical practice. Upon completion of this activity, participants should be better able to: Recognize the role of biomarker testing for the management of HER2-overexpressing NSCLC; Evaluate the clinical significance of new and emerging HER2-targeting ADCs for HER2-overexpressing NSCLC; and Apply strategies to optimize the use of HER2 targeting ADCs in patients with NSCLC.

Please visit answersincme.com/FBG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and cardiac sonography discuss best practices for using echocardiography for the diagnosis and management of obstructive hypertrophic cardiomyopathy, highlighting how echocardiography may guide treatment decisions with cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Review guideline-recommended approaches to diagnose obstructive HCM; Evaluate how cardiac myosin inhibitors fit into the care of patients with obstructive HCM; Specify how echocardiogram may help guide treatment decisions for patients with HCM; and Outline strategies to optimally utilize echocardiography to monitor patients on cardiac myosin inhibitors.

Please visit answersincme.com/QWE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure. Upon completion of this activity, participants should be better able to: Identify the evolving role of mineralocorticoid receptor antagonists (MRAs) to treat patients with heart failure; Evaluate clinical implications of the latest data on nonsteroidal MRAs for the treatment of heart failure and mildly reduced ejection fraction (HFmrEF) or heart failure and preserved ejection fraction (HFpEF), in the context of current standard-of-care; and Describe strategies to incorporate nonsteroidal MRAs into the treatment plans of patients with HFmrEF or HFpEF.

Please visit answersincme.com/860/97851223-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in lung cancer discuss the practical application of immunotherapy-based regimens for the treatment of extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Review the clinical impact of immunotherapy-based regimens for the management of small-cell lung cancer (SCLC); and Outline personalized treatment strategies to address key complexities affecting the optimal, real-world management of patients with SCLC.

Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.

Please visit answersincme.com/ZDE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses best practices for implementing biomarker testing in non-small cell lung cancer (NSCLC) management. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations for biomarker testing to the management of patients with NSCLC, Outline practical strategies within the multidisciplinary team to optimize biomarker testing for patients with NSCLC; and Discuss methods to link biomarker testing to treatment decision-making for patients with NSCLC.

Please visit answersincme.com/FXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infectious disease discusses management of refractory Mycobacterium avium complex (MAC) pulmonary disease. Upon completion of this activity, participants should be better able to: Identify patients with refractory Mycobacterium avium complex (MAC) pulmonary disease in a timely manner; Review guideline-recommended therapeutic approaches to enhance the treatment plan for patients with refractory MAC pulmonary disease; and Outline clinical strategies to optimize long-term care for patients with refractory MAC pulmonary disease.

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/YCT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with asthma who may benefit from treatment intensification with biologic therapy; Outline the clinical impact of add-on biologics approved for the treatment of pediatric patients with moderate to severe asthma; and Identify patient-centered strategies to optimize outcomes for pediatric patients with inadequately controlled moderate to severe asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

Please visit answersincme.com/CZY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in pediatric asthma discuss early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Identify the role of early intervention with biologics on the long-term lung function of pediatric patients with moderate to severe asthma; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate to severe asthma on lung function; and Describe evidence-based strategies for optimizing long-term lung function in pediatric patients with moderate to severe asthma. This activity is intended for US healthcare professionals only.